Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. - Wikidata - wikimedia - TriplyDB

Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.

Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.

http://www.wikidata.org/entity/Q34017354

about

Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum Complexes Mucin-Inspired Thermoresponsive Synthetic Hydrogels Induce Stasis in Human Pluripotent Stem Cells and Human Embryos.Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner.The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair.DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Targeting syndecans: a promising strategy for the treatment of cancer.DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.Enhancing CHK1 inhibitor lethality in glioblastoma.ATR/CHK1 inhibitors and cancer therapy.YM155 exerts potent cytotoxic activity against quiescent (G0/G1) multiple myeloma and bortezomib resistant cells via inhibition of survivin and Mcl-1.Cancer Cell Glycocalyx and Its Significance in Cancer Progression

P2860

Q24289008-57A3D83F-FF89-463A-A3CC-EC2C2C1532BF Q27300735-93AFC770-150F-4C0B-8756-B3401556BBE1 Q28540339-24147D92-58B2-4BAA-B39A-443F389DB8B7 Q33426534-0A36FAC8-4778-4730-96C6-E2DDBA72C12E Q35809470-97EEECA5-5060-4F06-BCCB-9C0F408F31CB Q35835097-E03335E8-35AC-4620-8F5B-3AEED8FF6A69 Q36412841-7691A0A7-6EAA-4A79-9762-78CECA00931F Q36907824-88C598E7-A957-4DC7-8AC1-7BB72AE37FC8 Q36927012-6A7F338D-60E7-4446-A12C-4AAC3E7AAF36 Q37505517-C231942D-8499-46D7-9F2F-1097C01B72BF Q37697253-42AC83D7-1795-457A-A17D-37FD67E7C964 Q38082795-9A250670-AE1A-443C-9EE5-12D8606A55D0 Q38756630-E6AF2785-ECCF-4D4A-A767-580D61A349DD Q39277209-21FEDEC6-C371-4F75-892D-1177A6528311 Q40063670-94FC80BD-93EE-4B4D-B7FB-EA800C008F07 Q41767263-48901375-45FE-40DF-B9FA-272F9D43D753 Q47622968-E807721E-1F9C-4562-8057-9E3B7D2D4969 Q49238703-D284C362-A100-4022-A3E0-F00EC1D1942A Q57168005-DA27B5A1-E75E-4AE8-84F9-0DDD39845A34

P2860

Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.

http://www.wikidata.org/entity/Q34017354

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Cytokinetically quiescent (G0/ ...... inhibition of Chk1 and MEK1/2.

@ast

Cytokinetically quiescent (G0/ ...... inhibition of Chk1 and MEK1/2.

@en

Cytokinetically quiescent

@nl

type

label

Cytokinetically quiescent (G0/ ...... inhibition of Chk1 and MEK1/2.

@ast

Cytokinetically quiescent (G0/ ...... inhibition of Chk1 and MEK1/2.

@en

Cytokinetically quiescent

@nl

prefLabel

Cytokinetically quiescent (G0/ ...... inhibition of Chk1 and MEK1/2.

@ast

Cytokinetically quiescent (G0/ ...... inhibition of Chk1 and MEK1/2.

@en

Cytokinetically quiescent

@nl

P1433

Q34017354-5347E04B-B509-4814-9B6E-252C010E2C55

P1476

Q34017354-AA762DBB-CE86-4D4C-A9F0-904ADD5174F0

P2093

Q34017354-0A0832BC-97BC-44AB-AAEC-E585C0128168

Q34017354-3A165711-7C2C-4442-8835-0568517539D8

Q34017354-4F66092E-5FAD-43BD-84C8-FE60E849EBA5

Q34017354-52CC48F1-13A6-464C-9388-9FA64B0CFB2F

Q34017354-67A73768-DEF5-4B0C-9B93-4F32F591FD4B

Q34017354-8C227764-80C1-47F2-B6E3-D22E90DB9C81

Q34017354-8F1565EC-259B-4FBD-8C73-88305284BE9A

Q34017354-AD343006-23D1-4E3C-BEFA-3FE88D20EEC1

Q34017354-C09649EA-6F17-41E8-85FE-A4287FD394A9

Q34017354-E1DFED79-3CE2-473A-B71D-3A1B319EFE7B

P2860

Q34017354-045C3EE4-8FE7-42D0-B377-4C09916851BA

Q34017354-11600F11-DC63-47AA-B928-033461FD2309

Q34017354-12E2D418-7BE1-429F-B77D-D320C900AA51

Q34017354-173F4B92-7B0E-45AF-BAD4-B267A4E6CDC6

Q34017354-26175AE4-20D3-4D38-AECB-AD68AEE5F60C

Q34017354-26CC2FA7-A8C9-413C-AAED-7C9926E4FA2F

Q34017354-2716A146-1748-456A-8DCF-226320ED1BDC

Q34017354-2AAA6C3D-1C1A-4DC9-B4DE-8EBD7B518F91

Q34017354-2AEEE42C-BF4F-4ADC-A8B7-FD2DB00014D6

Q34017354-2C493359-F112-4A86-AF2E-0F694C028265

P304

Q34017354-8394B369-581F-4FCC-8B13-57429499EC34

P31

Q34017354-DBB7AA72-55DC-4907-94EC-3B60A8D57A0A

P356

Q34017354-0184A346-271A-48FD-8283-031B84C8ECF4

P407

Q34017354-8AFEFA8E-3FE6-4E6F-B4D1-B7241F686DC0

P433

Q34017354-887B7947-E067-4C0C-ABA8-09C5D66D4A03

P478

Q34017354-DFA7FC16-DF13-4249-8A8C-E18A4E09AA08

P50

Q34017354-5CF89069-C74D-41CD-9C0D-0C495AC5F7FB

P577

Q34017354-53AAC46C-D1BB-4539-BE73-A7C026974F94

P5875

Q34017354-B88A49C2-63DB-4FF8-892F-35A544E09B22

P698

Q34017354-6236AEDF-6A3A-401E-8CC4-13EF1F6A6A3D

P932

Q34017354-461D5B2A-B52F-4094-9A8E-F98880658E50

P356

BLOOD-2011-02-339432

P1433

P1476

Cytokinetically quiescent (G0/ ...... inhibition of Chk1 and MEK1/2.

@en

P2093

Jessica Felthousen

http://www.w3.org/2001/XMLSchema#string

Jorge A Almenara

http://www.w3.org/2001/XMLSchema#string

Leena E Youssefian

http://www.w3.org/2001/XMLSchema#string

Lora B Kramer

http://www.w3.org/2001/XMLSchema#string

Shuang Chen

http://www.w3.org/2001/XMLSchema#string

Steven Grant

http://www.w3.org/2001/XMLSchema#string

Wesley W Bodie

http://www.w3.org/2001/XMLSchema#string

Xin-Yan Pei

http://www.w3.org/2001/XMLSchema#string

Yukie Takabatake

http://www.w3.org/2001/XMLSchema#string

Yun Dai

http://www.w3.org/2001/XMLSchema#string

P2860

ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL

DNA nucleotide excision repair-dependent signaling to checkpoint activation

The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair

Switching from repression to activation: microRNAs can up-regulate translation

Regulatory interactions between the checkpoint kinase Chk1 and the proteins of the DNA-dependent protein kinase complex

Cell-cycle checkpoints and cancer

Hyperactive Ras in developmental disorders and cancer

Principles of cancer therapy: oncogene and non-oncogene addiction

Chk1 and Chk2 kinases in checkpoint control and cancer

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

P304

5189-5200

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-02-339432

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51632062

http://www.w3.org/2001/XMLSchema#string

P698

21911831

http://www.w3.org/2001/XMLSchema#string

P932

3217403

http://www.w3.org/2001/XMLSchema#string